KRON vs. DSGN, ESPR, NBTX, MDWD, CRDF, IMAB, PRQR, SOPH, SCPH, and MNPR
Should you be buying Kronos Bio stock or one of its competitors? The main competitors of Kronos Bio include Design Therapeutics (DSGN), Esperion Therapeutics (ESPR), Nanobiotix (NBTX), MediWound (MDWD), Cardiff Oncology (CRDF), I-Mab (IMAB), ProQR Therapeutics (PRQR), SOPHiA GENETICS (SOPH), scPharmaceuticals (SCPH), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry.
Kronos Bio vs. Its Competitors
Kronos Bio (NASDAQ:KRON) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.
64.1% of Kronos Bio shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 24.4% of Kronos Bio shares are held by insiders. Comparatively, 31.2% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Kronos Bio has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.
Design Therapeutics has a net margin of 0.00% compared to Kronos Bio's net margin of -701.53%. Design Therapeutics' return on equity of -22.85% beat Kronos Bio's return on equity.
Kronos Bio currently has a consensus target price of $1.63, indicating a potential upside of 84.66%. Design Therapeutics has a consensus target price of $4.00, indicating a potential upside of 6.10%. Given Kronos Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Kronos Bio is more favorable than Design Therapeutics.
In the previous week, Kronos Bio's average media sentiment score of 0.00 equaled Design Therapeutics'average media sentiment score.
Design Therapeutics has lower revenue, but higher earnings than Kronos Bio. Design Therapeutics is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Kronos Bio beats Design Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Kronos Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kronos Bio Competitors List
Related Companies and Tools
This page (NASDAQ:KRON) was last updated on 7/4/2025 by MarketBeat.com Staff
